Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry - Report - MDSpire
Advertisement
Overview of Findings: Real-World Outcomes of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children Aged 12 and Younger from the PEDISTAD Registry
Clinical Report: Real-World Outcomes of Systemic Therapies for Atopic Dermatitis
Overview
This report summarizes findings from the PEDISTAD registry regarding systemic therapies for moderate-to-severe atopic dermatitis in children aged 12 and younger. The data highlights the effectiveness and safety of various treatment options, including biologics and JAK inhibitors.
Background
Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly impacts the quality of life in pediatric patients. Understanding real-world treatment outcomes is essential for optimizing therapeutic strategies and improving patient care. Recent guidelines emphasize the use of systemic therapies for moderate-to-severe cases after topical treatments have been optimized.
Data Highlights
No numerical data available in the provided source material.
Key Findings
Systemic therapies, including biologics and JAK inhibitors, are recommended for moderate-to-severe AD in children.
Dupilumab has shown significant efficacy in improving EASI-75 responses and quality of life in children aged 6-11 years.
Safety profiles of newer treatments, such as dupilumab, indicate no increased risk of overall infections in young patients.
Current guidelines discourage the use of systemic corticosteroids except as short-term bridge therapy.
Real-world evidence supports the effectiveness of targeted therapies over traditional immunosuppressants.
Clinical Implications
Clinicians should consider biologics and JAK inhibitors as first-line systemic treatments for children with moderate-to-severe atopic dermatitis. Ongoing monitoring and risk-benefit assessments are crucial, especially when using oral JAK inhibitors in severe cases.
Conclusion
The findings from the PEDISTAD registry underscore the importance of utilizing effective systemic therapies for managing atopic dermatitis in pediatric patients. Continued research and adherence to updated guidelines will enhance treatment outcomes.
by Amy S. Paller, Danielle Marcoux, Michele Ramien, Eulalia Baselga, Vania Oliveira de Carvalho, Ledit R. F. Ardusso, Marlies de Graaf, Suzanne Pasmans, Mirna Toledo-Bahena, Cory J. Rubin, Joel C. Joyce, Lara Wine Lee, Rajan Gupta, Bryan Adams, Marius Ardeleanu, Annie Zhang
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
